These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
609 related articles for article (PubMed ID: 31846838)
1. Phospholipids and cholesterol: Inducers of cancer multidrug resistance and therapeutic targets. Kopecka J; Trouillas P; Gašparović AČ; Gazzano E; Assaraf YG; Riganti C Drug Resist Updat; 2020 Mar; 49():100670. PubMed ID: 31846838 [TBL] [Abstract][Full Text] [Related]
2. What sustains the multidrug resistance phenotype beyond ABC efflux transporters? Looking beyond the tip of the iceberg. Alexa-Stratulat T; Pešić M; Gašparović AČ; Trougakos IP; Riganti C Drug Resist Updat; 2019 Sep; 46():100643. PubMed ID: 31493711 [TBL] [Abstract][Full Text] [Related]
3. Improvement of conventional anti-cancer drugs as new tools against multidrug resistant tumors. Dallavalle S; Dobričić V; Lazzarato L; Gazzano E; Machuqueiro M; Pajeva I; Tsakovska I; Zidar N; Fruttero R Drug Resist Updat; 2020 May; 50():100682. PubMed ID: 32087558 [TBL] [Abstract][Full Text] [Related]
5. Understanding of human ATP binding cassette superfamily and novel multidrug resistance modulators to overcome MDR. Mohammad IS; He W; Yin L Biomed Pharmacother; 2018 Apr; 100():335-348. PubMed ID: 29453043 [TBL] [Abstract][Full Text] [Related]
6. Lipid raft modulation by Rp1 reverses multidrug resistance via inactivating MDR-1 and Src inhibition. Yun UJ; Lee JH; Koo KH; Ye SK; Kim SY; Lee CH; Kim YN Biochem Pharmacol; 2013 May; 85(10):1441-53. PubMed ID: 23473805 [TBL] [Abstract][Full Text] [Related]
7. Molecular Modeling Strategies of Cancer Multidrug Resistance. Yalcin-Ozkat G Drug Resist Updat; 2021 Dec; 59():100789. PubMed ID: 34973929 [TBL] [Abstract][Full Text] [Related]
8. Drug resistance-associated changes in sphingolipids and ABC transporters occur in different regions of membrane domains. Hinrichs JW; Klappe K; van Riezen M; Kok JW J Lipid Res; 2005 Nov; 46(11):2367-76. PubMed ID: 16150833 [TBL] [Abstract][Full Text] [Related]
9. Reversal effect of FW-04-806, a macrolide dilactone compound, on multidrug resistance mediated by ABCB1 and ABCG2 in vitro and in vivo. Zhang Z; Ma C; Li P; Wu M; Ye S; Fu L; Xu J Cell Commun Signal; 2019 Sep; 17(1):110. PubMed ID: 31472682 [TBL] [Abstract][Full Text] [Related]
10. Reversal of multidrug resistance by Marsdenia tenacissima and its main active ingredients polyoxypregnanes. To KKW; Wu X; Yin C; Chai S; Yao S; Kadioglu O; Efferth T; Ye Y; Lin G J Ethnopharmacol; 2017 May; 203():110-119. PubMed ID: 28363522 [TBL] [Abstract][Full Text] [Related]
11. Lipids as a target for drugs modulating multidrug resistance of cancer cells. Hendrich AB; Michalak K Curr Drug Targets; 2003 Jan; 4(1):23-30. PubMed ID: 12528987 [TBL] [Abstract][Full Text] [Related]
12. MDR reversal and pro-apoptotic effects of statins and statins combined with flavonoids in colon cancer cells. Palko-Łabuz A; Środa-Pomianek K; Wesołowska O; Kostrzewa-Susłow E; Uryga A; Michalak K Biomed Pharmacother; 2019 Jan; 109():1511-1522. PubMed ID: 30551403 [TBL] [Abstract][Full Text] [Related]
13. Multidrug resistance: retrospect and prospects in anti-cancer drug treatment. Pérez-Tomás R Curr Med Chem; 2006; 13(16):1859-76. PubMed ID: 16842198 [TBL] [Abstract][Full Text] [Related]
14. β-carotene reverses multidrug resistant cancer cells by selectively modulating human P-glycoprotein function. Teng YN; Sheu MJ; Hsieh YW; Wang RY; Chiang YC; Hung CC Phytomedicine; 2016 Mar; 23(3):316-23. PubMed ID: 26969385 [TBL] [Abstract][Full Text] [Related]
15. Dacomitinib antagonizes multidrug resistance (MDR) in cancer cells by inhibiting the efflux activity of ABCB1 and ABCG2 transporters. Fan YF; Zhang W; Zeng L; Lei ZN; Cai CY; Gupta P; Yang DH; Cui Q; Qin ZD; Chen ZS; Trombetta LD Cancer Lett; 2018 May; 421():186-198. PubMed ID: 29331420 [TBL] [Abstract][Full Text] [Related]
16. Targeted disruption of mitochondria potently reverses multidrug resistance in cancer therapy. Liu D; Rong H; Chen Y; Wang Q; Qian S; Ji Y; Yao W; Yin J; Gao X Br J Pharmacol; 2022 Jul; 179(13):3346-3362. PubMed ID: 35040123 [TBL] [Abstract][Full Text] [Related]
17. Reversing agents for ATP-binding cassette (ABC) transporters: application in modulating multidrug resistance (MDR). Lee CH Curr Med Chem Anticancer Agents; 2004 Jan; 4(1):43-52. PubMed ID: 14754411 [TBL] [Abstract][Full Text] [Related]
18. Not only P-glycoprotein: Amplification of the ABCB1-containing chromosome region 7q21 confers multidrug resistance upon cancer cells by coordinated overexpression of an assortment of resistance-related proteins. Genovese I; Ilari A; Assaraf YG; Fazi F; Colotti G Drug Resist Updat; 2017 May; 32():23-46. PubMed ID: 29145976 [TBL] [Abstract][Full Text] [Related]
19. Multidrug resistance: molecular mechanisms and clinical relevance. Ling V Cancer Chemother Pharmacol; 1997; 40 Suppl():S3-8. PubMed ID: 9272126 [TBL] [Abstract][Full Text] [Related]
20. Treatment with HIV-Protease Inhibitor Nelfinavir Identifies Membrane Lipid Composition and Fluidity as a Therapeutic Target in Advanced Multiple Myeloma. Besse L; Besse A; Stolze SC; Sobh A; Zaal EA; van der Ham AJ; Ruiz M; Phuyal S; Büchler L; Sathianathan M; Florea BI; Borén J; Ståhlman M; Huber J; Bolomsky A; Ludwig H; Hannich JT; Loguinov A; Everts B; Berkers CR; Pilon M; Farhan H; Vulpe CD; Overkleeft HS; Driessen C Cancer Res; 2021 Sep; 81(17):4581-4593. PubMed ID: 34158378 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]